CARLSBAD, Calif.--(BUSINESS WIRE)--Encore Therapeutics, Inc. (“ETI”) today reported that it has created a proprietary nano-emulsion intravenous formulation of progesterone that is suitable for the treatment of stroke and traumatic brain Injury, or TBI. Both stroke and TBI are major unmet needs with 500,000 and 1.4 million new cases, respectively, reported each year in the United States and no effective treatments for either disorder.
